You have free access to this content

Cancer

Cover image for Cancer

1 May 2010

Volume 116, Issue 9

Pages 2065–2285

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. You have free access to this content
    2. You have free access to this content
  2. Editorial

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. You have free access to this content
      Intra-arterial chemotherapy for head and neck cancer : Is There a Verdict? (pages 2068–2070)

      K. Thomas Robbins, Stephen B. Howell and James Scott Williams

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.24930

      Although it would appear that there is no difference in outcomes for intra-arterial (IA) versus intravenous cisplatin chemoradiotherapy, one must consider the technique by which the tumors were infused. The authors used the less effective method of bilateral infusion in 58% of patients compared to <5% by us. This large difference could have affected the outcome thus leaving the value of IA cisplatin infusion in question.

  3. Review Article

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. You have free access to this content
      A new era in anticancer peptide vaccines (pages 2071–2080)

      Sonia A. Perez, Eric von Hofe, Nikoletta L. Kallinteris, Angelos D. Gritzapis, George E. Peoples, Michael Papamichail and Constantin N. Baxevanis

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.24988

      • original image

      Modified polypeptide vaccines are powerful tools for active immunization strategies. In this review, the authors observed that the results from combined therapeutic strategies applied during early vaccination were encouraging for the future of cancer immunotherapy.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. Disease Site

      Breast Disease
      You have free access to this content
      Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer (pages 2081–2089)

      Bent Ejlertsen, Henning T. Mouridsen, Maj-Britt Jensen, Jørn Andersen, Michael Andersson, Claus Kamby, Ann S. Knoop and for the Danish Breast Cancer Cooperative Group

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.24969

      • original image
      • original image
      • original image

      In the Danish Breast Cancer Cooperative Group Trial 77B, oral cyclophosphamide alone and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) significantly improved disease-free and overall survival compared with no systemic therapy in premenopausal patients who had high-risk breast cancer. No significant differences were observed in disease-free or overall survival between patients who were randomized to receive oral cyclophosphamide or CMF.

    2. You have free access to this content
      American Society of Clinical Oncology-recommended surveillance and physician specialty among long-term breast cancer survivors (pages 2090–2098)

      Kerry Hollowell, Courtney L. Olmsted, Anne S. Richardson, H. Keith Pittman, Lisa Bellin, Lorraine Tafra and Kathryn M. Verbanac

      Article first published online: 2 MAR 2010 | DOI: 10.1002/cncr.25038

      • original image
      • original image
      • original image
      • original image
      • original image

      Compliance with current surveillance guidelines needs improvement among all providers. Specialists more consistently followed American Society of Clinical Oncology guidelines for surveillance frequency and care. If transfer of care to a primary care physician occurs, it should be formalized and include follow-up recommendations and defined physician responsibilities.

    3. You have free access to this content
      Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy (pages 2099–2105)

      Bo Yu, Nataki Douglas, Michel J. Ferin, Gary S. Nakhuda, Katherine Crew, Rogerio A. Lobo and Dawn L. Hershman

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25037

      • original image
      • original image

      In young women with breast cancer, chemotherapy decreases mullerian inhibitory substance (MIS) rapidly and dramatically. Rapid reductions in MIS do not appear to predict subsequent menstrual function. Ovarian reserve and endocrine function may be affected differently by chemotherapy.

    4. Gastrointestinal Disease
      You have free access to this content
      Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases (pages 2106–2114)

      Terence C. Chua, Kelly Thornbury, Akshat Saxena, Winston Liauw, Derek Glenn, Jing Zhao and David L. Morris

      Article first published online: 17 FEB 2010 | DOI: 10.1002/cncr.24952

      • original image
      • original image
      • original image
      • original image
      • original image

      This study presents a single institution's experience of treating unresectable colorectal cancer pulmonary metastases and examines the role of combining systemic treatment with local ablation through the use of modern-agent systemic chemotherapy and radiofrequency ablation.

    5. You have free access to this content
      Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use (pages 2115–2125)

      Paul Rozen, Doron Comaneshter, Zohar Levi, Rachel Hazazi, Alex Vilkin, Eran Maoz, Shlomo Birkenfeld and Yaron Niv

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.25012

      Quantitative immunochemical fecal occult blood screening tests are used for colorectal cancer screening. However, there is no agreement on the number of tests to prepare and the cutoff to use to obtain optimal sensitivity and to avoid unnecessary colonoscopy. Analysis of data from 1682 colonoscopy patients, by investigators who also prepared the fecal tests, showed that 2 or 3 tests analyzed at the lowest threshold provided the highest sensitivity.

    6. Genitourinary Disease
      You have free access to this content
      Quality of end-of-life care in low-income, uninsured men dying of prostate cancer (pages 2126–2131)

      Jonathan Bergman, Amanda C. Chi and Mark S. Litwin

      Article first published online: 2 MAR 2010 | DOI: 10.1002/cncr.25039

      The quality of end-of-life care in disadvantaged men prospectively enrolled in a public assistance program was assessed. End-of-life care in disadvantaged men dying of prostate cancer, who enrolled in a comprehensive statewide assistance program, is high-quality.

    7. Discipline

      Genitourinary Disease
      You have free access to this content
      Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer (pages 2132–2139)

      Manpreet K. Chadha, Lili Tian, Terry Mashtare, Valencia Payne, Carrie Silliman, Ellis Levine, Michael Wong, Candace Johnson and Donald L. Trump

      Article first published online: 17 FEB 2010 | DOI: 10.1002/cncr.24973

      • original image

      In the current phase 2 study, weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) 74 μg weekly on Day 2 combined with oral dexamethasone 4 mg weekly on Days 1 and 2 for men with castration-resistant prostate cancer was well tolerated but failed to produce any significant clinical or prostate-specific antigen response.

    8. Disease Site

      Genitourinary Disease
      You have free access to this content
      Increased risk of high-grade prostate cancer among infertile men (pages 2140–2147)

      Thomas J. Walsh, Michael Schembri, Paul J. Turek, June M. Chan, Peter R. Carroll, James F. Smith, Michael L. Eisenberg, Stephen K. Van Den Eeden and Mary S. Croughan

      Article first published online: 22 MAR 2010 | DOI: 10.1002/cncr.25075

      • original image

      Men with male factor infertility may have a higher risk of developing clinically significant prostate cancer. Abnormalities in semen parameters were identified 10 years before a diagnosis of cancer, suggesting that early prostate cancer screening may be warranted in men with male factor infertility.

    9. Head and Neck Disease
      You have free access to this content
      hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer (pages 2148–2158)

      Harriet E. Gee, Carme Camps, Francesca M. Buffa, Shalini Patiar, Stuart C. Winter, Guy Betts, Jarrod Homer, Rogan Corbridge, Graham Cox, Catharine M. L. West, Jiannis Ragoussis and Adrian L. Harris

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25009

      • original image
      • original image
      • original image
      • original image
      • original image

      In a series of 46 patients with head and neck squamous cell carcinoma, the level of the microRNA hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). In addition, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and a short overall survival (P = .008).

    10. You have free access to this content
      Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial (pages 2159–2165)

      Coen R. N. Rasch, Michael Hauptmann, Jan Schornagel, Oda Wijers, Jan Buter, Theo Gregor, Ruud Wiggenraad, Jan Paul de Boer, Annemiek H. Ackerstaff, Robert Kroger, Frank J. P. Hoebers and Alfons J. M. Balm

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.24916

      • original image

      Cisplatin-based intra-arterial chemoradiation is not superior to intravenous chemoradiation for advanced stage IV head and neck cancer.

      Corrected by:

      Erratum: Erratum: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

      Vol. 116, Issue 15, 3750, Article first published online: 11 MAY 2010

    11. You have free access to this content
      Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience (pages 2166–2173)

      Aatur D. Singhi and William H. Westra

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.25033

      • original image
      • original image
      • original image
      • original image

      Human papillomavirus (HPV) analysis is sometimes performed as a part of clinical care for patients with cancers of the head and neck, providing opportunities to compare various HPV detection assays and evaluate specific roles for HPV detection in the clinical arena. A feasible strategy that incorporates both p16 immunohistochemistry and HPV in situ hybridization is able to detect HPV in a remarkably high percentage of oropharyngeal carcinomas, and is increasingly used to estimate clinical outcomes, establish tumor classification, and determine site of tumor origin.

    12. Hematologic Malignancies
      You have free access to this content
      Cause of death in patients with lower-risk myelodysplastic syndrome (pages 2174–2179)

      Farshid Dayyani, Anthony P. Conley, Sara S. Strom, William Stevenson, Jorge E. Cortes, Gautam Borthakur, Stefan Faderl, Susan O'Brien, Sherry Pierce, Hagop Kantarjian and Guillermo Garcia-Manero

      Article first published online: 16 FEB 2010 | DOI: 10.1002/cncr.24984

      • original image
      • original image
      • original image

      The cause of death in the majority of patients with lower-risk myelodysplastic syndrome is related to their underlying condition. Therefore, the benefit of earlier therapeutic intervention in this patient cohort should be further investigated.

    13. You have free access to this content
      Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia (pages 2180–2187)

      Neil E. Kay, Wenting Wu, Brian Kabat, Betsy LaPlant, Thomas S. Lin, John C. Byrd, Diane F. Jelinek, Michael R. Grever, Clive S. Zent, Timothy G. Call and Tait D. Shanafelt

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25028

      • original image

      Pentostatin-based combination treatments for previously untreated chronic lymphocytic leukemia (CLL) are most optimal when cyclophosphamide is added to pentostatin and rituximab. Whereas pentostatin and rituximab are reported to be effective in previously untreated CLL patients, the level of response is reduced compared with the combination of pentostatin, cyclophosphamide, and rituximab but does benefit from reduced toxicity.

    14. You have free access to this content
      Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma (pages 2188–2200)

      Davide Rossi, Marco Fangazio, Lorenzo De Paoli, Alessia Puma, Paola Riccomagno, Valeria Pinto, Paola Zigrossi, Antonio Ramponi, Guido Monga and Gianluca Gaidano

      Article first published online: 2 MAR 2010 | DOI: 10.1002/cncr.24959

      • original image
      • original image
      • original image
      • original image

      The objective of this study was to explore the role of serum beta-2 microglobulin in predicting the risk of progression of asymptomatic multiple myeloma to symptomatic disease. The findings indicated that 1) serum beta-2 microglobulin is an independent predictor of asymptomatic multiple myeloma progression, and 2) serum beta-2 microglobulin adds prognostic information when combined with the most widely used prognosticators of asymptomatic multiple myeloma progression.

    15. You have free access to this content
      The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation (pages 2201–2207)

      Clive S. Zent, Betsy R. LaPlant, Patrick B. Johnston, Timothy G. Call, Thomas M. Habermann, Ivana N. Micallef and Thomas E. Witzig

      Article first published online: 17 FEB 2010 | DOI: 10.1002/cncr.25005

      • original image
      • original image

      Everolimus has modest single-agent clinical efficacy in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, but can mobilize CLL cells from lymphoid tissue into the circulation, and thus has the potential to be useful in combination therapy.

    16. Hepatobiliary Disease
      You have free access to this content
      The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma (pages 2208–2214)

      Stefano Cereda, Paolo Passoni, Michele Reni, Maria G. Viganò, Luca Aldrighetti, Roberto Nicoletti and Eugenio Villa

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.24970

      • original image

      Biliary tract adenocarcinoma is an uncommon tumor with a poor prognosis and no standard systemic treatment. The cisplatin, epirubicin, 5-fluorouracil, and gemcitabine (PEFG) regimen is effective as an upfront treatment for advanced pancreatic cancer which demonstrated, in this study, to be also active with a manageable toxicity profile for patients with advanced biliary tract cancer.

    17. Melanoma
      You have free access to this content
      Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center (pages 2215–2223)

      Mauricio A. Moreno, Dianna B. Roberts, Michael E. Kupferman, Franco DeMonte, Adel K. El-Naggar, Michelle Williams, David S. Rosenthal and Ehab Y. Hanna

      Article first published online: 2 MAR 2010 | DOI: 10.1002/cncr.24976

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      This is a large, contemporary series of mucosal melanomas of the nose and paranasal sinuses treated in a tertiary cancer center. We found that the American Joint Committee on Cancer TNM classification system provides accurate prognostic information and should be the staging system of choice. The use of adjuvant radiation therapy improved locoregional control only when doses higher than 54 Gy and standard fractionation were used. Histological features such as pigmentation and pseudopapillary architecture were associated with a worse outcome.

    18. You have free access to this content
      Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2–positive uveal melanoma (pages 2224–2233)

      Dimitrios Mougiakakos, C. Christian Johansson, Eric Trocme, Charlotta All-Ericsson, Mario A. Economou, Olle Larsson, Stefan Seregard and Rolf Kiessling

      Article first published online: 5 MAR 2010 | DOI: 10.1002/cncr.24999

      • original image
      • original image
      • original image

      In this study on uveal melanoma (UM), a relatively infrequent type of cancer, the authors observed that high expression of cyclooxygenase-2 (COX-2) was associated with the presence and intratumoral localization of regulatory T cells. The prevalence of intratumoral regulatory T cells, which the authors describe here in UM for the first time, is predictive of a shortened overall survival in patients with COX-2–positive UM.

    19. You have free access to this content
      Conditional survival estimates improve over time for patients with advanced melanoma : Results from a population-based analysis (pages 2234–2241)

      Yan Xing, George J. Chang, Chung-Yuan Hu, Robert L. Askew, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield, Anthony Lucci and Janice N. Cormier

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.24966

      • original image
      • original image
      • original image

      Five-year melanoma-specific conditional survival estimates improve dramatically over time for survivors with advanced stages of disease. These prognostic data are critical to patients for both treatment and nontreatment related life decisions.

    20. Neuro-Oncology
      You have free access to this content
      Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients (pages 2242–2249)

      Lindsay Kilburn, M. Fatih Okcu, Tao Wang, Yumei Cao, Amy Renfro-Spelman, Kenneth D. Aldape, Mark R. Gilbert and Melissa Bondy

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25006

      • original image
      • original image
      • original image
      • original image

      Glutathione S-transferase polymorphisms are associated with survival in patients with anaplastic glial brain tumors.

    21. You have free access to this content
      Radiosurgical decompression of metastatic epidural compression (pages 2250–2257)

      Samuel Ryu, Jack Rock, Rajan Jain, Mei Lu, Joseph Anderson, Jian-Yue Jin, Mark Rosenblum, Benjamin Movsas and Jae Ho Kim

      Article first published online: 5 MAR 2010 | DOI: 10.1002/cncr.24993

      • original image
      • original image

      Epidural decompression was achieved by spine radiosurgery of malignant epidural spinal cord compression. More than 80% of the patients with epidural compression showed radiographic improvement of thecal sac patency and neurological improvement or preservation.

    22. Sarcoma
      You have free access to this content
      Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) (pages 2258–2265)

      Veridiana Pires de Camargo, Mary L. Keohan, David R. D'Adamo, Cristina R. Antonescu, Murray F. Brennan, Samuel Singer, Linda S. Ahn and Robert G. Maki

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25089

      • original image
      • original image
      • original image

      In this single–institution analysis, anthracyclines and hormonal therapy appeared to be the most active agents against desmoid tumors. Patients with desmoid tumors should be considered for systemic therapy before undergoing potentially morbid or mutilating surgery.

    23. Discipline

      Pediatric Oncology
      You have free access to this content
      Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents : A comparison of parameters used for the Fédération Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems (pages 2266–2274)

      Joseph D. Khoury, Cheryl M. Coffin, Sheri L. Spunt, James R. Anderson, William H. Meyer and David M. Parham

      Article first published online: 17 FEB 2010 | DOI: 10.1002/cncr.24929

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Two systems for grading soft tissue sarcoma are widely used currently: the Pediatric Oncology Group and the Fédération Nationale des Centers de Lutte Contre le Cancer systems. In this study, we demonstrate that both systems provide an adequate prognostic measure of outcome for pediatric nonrhabdomyosarcoma soft tissue sarcomas, despite limitations in both systems, and that the mitotic index appears to be a key grading parameter in these childhood tumors.

    24. Symptom Control and Palliative Care
      You have free access to this content
      Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer (pages 2275–2283)

      Alice Nourissat, Isabelle Bairati, Elodie Samson, André Fortin, Michel Gélinas, Abdenour Nabid, François Brochet, Bernard Têtu and François Meyer

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.25041

      • original image

      The purpose of the study was to identify predictors of weight loss during radiotherapy (RT) in early stage head and neck (HN) cancer patients. Multivariate analyses showed that 5 factors can predict the occurrence of weight loss during RT in early stage HN cancer: the site of the tumor, the body weight at the beginning of RT, the stage of the disease, the presence of dysphagia and/or odynophagia at baseline, and the Karnofsky performance score.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. You have free access to this content
  6. Retraction

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Retraction
    1. You have free access to this content

SEARCH

SEARCH BY CITATION